The South African Health Products Regulatory Authority (SAHPRA) announced on Monday the registration of the Janssen Covid-19 vaccine on March 31, with conditions. SAHPRA CEO Dr Boitumelo Semete-Makokotlela explained that one of the conditions is that the vaccine be manufactured under conditions of Good Manufacturing Practices (GMP) as determined by SAHPRA and aligned with global best practice.